INTRODUCTION
============

A group of nuclear receptors, termed peroxisome proliferator-activated receptors (PPARs), was identified during the last decade \[[@B1]\]. These receptors, which belong to the steroid hormone receptor superfamily, bind to and are activated by fatty acids, eicosanoids, and numerous structurally dissimilar xenobiotics, known collectively as peroxisome proliferators (see \[[@B2]\]; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

Three related PPAR isotypes have been identified to date; PPAR *α*, PPAR *β/δ*, and PPAR *γ* \[[@B3], [@B4]\]. Studies have documented the existence of human forms of PPAR*α* (h PPAR*α*; \[[@B5], [@B6]\]) and PPAR*γ* (hPPAR *γ*; \[[@B7]\]). The tissue distribution pattern of hPPAR *α* mRNA is similar to that of the rat PPAR *α*. In both species PPAR *α* is highly expressed in brown adipose tissue, skeletal muscle, liver, heart, and kidney, while expressed at low levels in the brain and lung \[[@B6], [@B8]\]. The principal site of expression of PPAR *γ* is the adipose tissue, but this receptor is also expressed, albeit at lower levels, in many other tissues and cell types such as the retina, some parts of the immune system, mammary and colonic epithelium \[[@B9]\]. PPAR *δ* subtype is found in higher amounts than PPAR *α* and PPAR *γ* in almost all tissues examined, except the adipose tissue \[[@B10]\]. PPAR*δ* is expressed ubiquitously in the rat cerebellum, thalamus and cerebellar cortex \[[@B11]\], and specific PPAR*δ* agonists, and to a much lesser extent those of PPAR*γ*, stimulated oligodendrocyte differentiation in vitro \[[@B12]\].

![Chemical structures of representative PPAR agonists. PPAR*α*: Wy-14,643, PPAR *β*/*δ*: L-165041, and PPAR*γ*: Rosiglitazone.](30806.fig.001){#F1}

![Site-specific inhibition of carrageenan-induced paw inflammation by PPAR agonists. The hatched bar indicates the site at which PPAR agonists interfere with the inflammatory process.](30806.fig.002){#F2}

![A scheme depicting potential mechanisms via which anti-inflammatory effects are exerted by PPAR agonists. Solid lines represent potential PPAR-mediated effects. Dashed lines represent proposed mechanisms by which PPAR agonists may act via PPAR-independent mechanisms to diminish inflammation.](30806.fig.003){#F3}

###### 

Effect of various PPAR agonists on the temporal profile of paw edema. Rats were treated intraperitoneally with (100 mg/kg) of the PPAR*α* agonist PFOA (a), the PPAR*γ* agonist rosiglitazone (b), or the PPAR*δ* agonist L783484 (c) 30 minutes before induction of inflammation. As indicated by the arrow, carrageenan (1%, intraplantar) was injected at $t = 0$. Carrageenan-induced edema is reflected by an increase in paw thickness. Values represent mean ± SEM, $n = \text{5-8}$ rats per group; $^{\ast}P < .05$.
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###### 

Relative PPAR subtype-specificity of selected agonists.

  --------------- -------------- ----- -----
  Agonist         PPAR subtype         
  *α*             *β*/*δ*        *γ*   
                                       
  Wy-14,643       +++            −−−   \+
  L-165041        −−−            +++   \+
  Rosiglitazone   −−−            −−−   +++
  --------------- -------------- ----- -----

(+++): high activity, (+): weak activity, (−−−): no activity. Data are derived from references \[[@B4], [@B10], [@B12], [@B13]\].

###### 

Carrageenan-evoked proinflammatory mediators.

  ------------------ --------------------
  Mediator           Reference(s)
                     
  PGE2               \[[@B14]\]
  Nitric Oxide       \[[@B15]\]
  Superoxide anion   \[[@B15]\]
  Peroxynitrite      \[[@B15], [@B16]\]
  ------------------ --------------------

The chromosomal localization of the human and mouse PPAR genes has been identified \[[@B3]\]. The human PPAR*α* (h PPAR*α*) was mapped on chromosome 22 \[[@B3]\]. The hPPAR *γ* gene is located on chromosome 3 and the hPPAR *δ* has been assigned to chromosome 6 \[[@B3]\]. In the mouse, PPAR *γ* is located on chromosome 6, while PPAR *α* and PPAR *δ* are found on chromosomes 15 and 17, respectively \[[@B3]\].

DNA binding properties of PPARs
-------------------------------

The DNA binding domain is the most conserved domain among all nuclear hormone receptors, and is the hallmark of this superfamily of receptors. The DBD is formed by two zinc finger-like motifs folded in a globular structure that can recognize a DNA target composed of 6 nucleotides \[[@B3]\]. In most cases, nuclear hormone receptors bind as dimers to two copies of such a core motif, which constitute a functional hormone response element \[[@B3]\]. The spacing of the two motifs and their relative orientation determine which receptors bind to a given hormone response element \[[@B3]\].

Peroxisome proliferator-activated receptor response element (PPRE) is defined as a direct repeat of two core recognition motifs AGGTCA spaced by one nucleotide \[[@B3]\]. PPAR interacts with the upstream extended core hexamer of the PPRE \[[@B3]\]. The fact that some tissues express more than one PPAR isotype suggests the presence of PPAR isotype-specific PPRE recognition \[[@B3]\]. PPREs are classified into three functional groups: strong, intermediate, and weak elements. The PPAR DNA binding activity is modulated by, among other factors, the isotype of the 9-*cis* retinoid X receptor (RXR) heterodimeric partner \[[@B3]\]. Heterodimerization with RXR*γ* leads to binding to a strong element, while heterodimerization with RXR*α* favors binding to weak elements \[[@B3]\].

Ligand-binding properties of PPARs
----------------------------------

Compounds that trigger the expression of a reporter gene, when added to a cell culture medium, have been identified as PPAR activators. Studies revealed that these compounds selectively bind to various PPAR isotypes ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). It has been demonstrated that the prostaglandin 15-deoxy-$\Delta^{12,14}$-prostaglandin J~2~ and the antidiabetic thiazolidinediones are ligands for the PPAR*γ* \[[@B17], [@B18], [@B19]\]. Additionally, leukotriene B4 and several known peroxisome proliferating agents including Wy-14,643 and fibrates bind specifically to PPAR *α* \[[@B20], [@B21]\]. Fatty acids and eicosanoids also bind to PPAR*α*, with varying degrees of specificity \[[@B17], [@B22], [@B23]\]. A novel series of fibrates has recently been described as specific ligands for the PPAR *δ* subtype \[[@B4]\].

BIOLOGICAL ROLES OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
===============================================================

Although the focus of this review is on the involvement of PPARs in inflammatory diseases, it is important that we present a brief overview of the plethora of other functions controlled by these receptors. A PPAR subtype-specific role has been discovered in several important human diseases and pathological conditions \[[@B2], [@B4], [@B10], [@B19]\]. These receptors have been implicated in aging \[[@B24], [@B25]\], aging-related diseases \[[@B25], [@B26]\], inflammation and immunity \[[@B2], [@B10], [@B27], [@B28], [@B29]\], as well as in obesity \[[@B30], [@B31], [@B32], [@B33]\] and responsiveness to insulin \[[@B34]\]. Furthermore, PPARs have been reported to play a significant role in the regulation of fertility \[[@B2], [@B10], [@B35]\], and in cancer \[[@B2], [@B10], [@B36], [@B37], [@B38], [@B39]\].

Aging
-----

Senescence is associated with a decline in peroxisomal enzyme activities \[[@B24], [@B25]\]. Our most recent results suggest that peroxisomal decline, as a function of aging, may be the result of a decline in the availability of the obligatory PPAR*α* heterodimer partner RXR *α*, and not PPAR *α* itself in senescent animals \[[@B40]\]. The importance of this aging-associated peroxisomal enzyme deficiency lies in the fact that very-long-chain fatty acids are metabolized exclusively in peroxisomes \[[@B41]\]. Thus, PPARs appear to play an important role in maintaining membrane structure and function by regulating fatty acid balance \[[@B42], [@B43], [@B44]\].

Obesity and diabetes
--------------------

There are three variants of PPAR *γ*; *γ*1, *γ*2, and *γ*3 \[[@B3]\]. Adipose expression of PPAR *γ*2 mRNA increases in obese human subjects, with a strong positive correlation between the ratio of PPAR *γ*2 to *γ*1 and the body mass index \[[@B30]\]. Interestingly, differential expression of PPAR *γ* in intra-abdominal and subcutaneous adipose tissues in humans may underscore the association of visceral, but not subcutaneous, fat with obesity \[[@B31]\].

The recognition that PPAR *γ* is the receptor for the antidiabetic thiazolidinediones linked this receptor to glucose homeostasis in rodents and humans \[[@B21], [@B34]\]. There appears to be an inverse relationship between the level of PPAR *γ* mRNA and that of nonfunctional insulin receptors in human visceral adipose tissue \[[@B31]\]. PPAR *γ* ligands improve insulin sensitivity in vivo \[[@B32]\].

Cell cycle control and cancer
-----------------------------

A link between PPAR and cancer was first drawn after it became clear that PPAR agonists cause a dramatic increase in the incidence of liver tumors in mice and rats \[[@B24], [@B45]\]. Cell proliferation and peroxisomal production of H~2~O~2~ are two major factors enhanced by peroxisome proliferators and are implicated in liver cancer caused by these chemicals \[[@B36], [@B37]\]. Alternatively, several studies have shown that agonists of PPARs suppress apoptosis in the liver in a process mediated by PPAR *α* \[[@B46], [@B47]\]. Apoptosis appears to be a safeguard to prevent cells with DNA damage from progressing to a tumor \[[@B38]\], where hepatocytes resistant to apoptotic death may represent preferential targets for promotion by PPAR agonists.

The potential role of PPAR in cancer formation in humans is controversial \[[@B48]\]. While two recent studies implicated PPAR *γ* in promotion and development of colon cancer \[[@B31], [@B39]\], a third report indicated a possible protective role for PPAR *γ* agonists against colon cancer in humans \[[@B37]\]. It is evident that mice genetically predisposed to develop polyps in the colon show an increased number of polyps when subjected to PPAR *γ* agonists orally \[[@B31], [@B39]\]. Conversely, it was demonstrated that human colon tumor cell lines both in culture and in nude mice respond to PPAR *γ* agonists with a reduced rate of growth and an increased degree of differentiation \[[@B49]\]. We recently proposed that PPAR*γ* agonists may be beneficial in combating breast cancer in humans \[[@B50]\]. Furthermore, a recent report suggested that inhibiting PPAR *δ* may be responsible for reducing the incidence of colorectal cancer caused by nonsteroidal anti-inflammatory drugs \[[@B51]\]. Confirmation of the involvement of PPAR *δ* in colorectal cancer awaits more definitive studies using compounds specific to this PPAR subtype \[[@B4]\].

Fertility
---------

PPAR *δ* was detected in the uterus during embryo implantation in mice \[[@B35]\]. Similar to the expression pattern of the prostacyclin synthase enzyme, expression of PPAR *δ* was also induced in the stroma surrounding the implanting blastocyte and became localized in the decidual zone after implantation \[[@B35]\]. Supporting evidence for a PPAR *δ*-mediated role in fertility was obtained when activators of this PPAR subtype restored implantation in COX2 null mice \[[@B35]\]. This finding is in support of the hypothesis stipulating that prostacyclin and/or its metabolite(s) regulate embryo implantation by activating PPAR *δ* \[[@B4], [@B46]\]. PPAR *γ* also appears to play an important role in embryonic development \[[@B10]\]. Mice deficient in this PPAR subtype showed embryonic lethality, presumably a result of a major default in placental development \[[@B10]\]. PPAR *α*, however, does not appear to have a vital role in development \[[@B10]\].

MODULATION OF INFLAMMATORY RESPONSES BY AGONISTS OF PPARs
=========================================================

Inflammation
------------

Inflammation is a series of characteristic tissue responses to injury or insult. Elevated tissue levels of tumor necrosis factor *alpha* (TNF*α*), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), among other proinflammatory mediators, have been observed in experimental animal models of inflammation as well as in humans following trauma, severe blood loss, or sepsis. Onset of release of these mediators, and their tissue half-life vary significantly, based on the noxious stimuli to which tissue has been exposed \[[@B14]\]. Because of the impact of inflammation, acute or chronic, on the quality of life, intense research is directed toward the discovery of novel therapeutic agents to prevent/reverse these processes. Among the most promising compounds currently pursued toward achieving this goal are the PPAR agonists \[[@B4], [@B52]\].

Role of PPARs in inflammation
-----------------------------

Both PPAR*α* and PPAR*γ* receptor subtypes have been reported to regulate inflammatory responses, both in vivo and in vitro \[[@B53], [@B54]\]. However, the extent of this regulation, and indeed its direction, are controversial. No published reports are readily available on the involvement of PPAR*δ* in inflammation control. Potential modulation of inflammatory responses by PPAR*δ* agonists has only been recently investigated in our laboratories.

### PPAR*α*

The first indication of a role by PPAR in modulating inflammation was evidenced by the demonstration that Leukotriene B4 (LTB4), a potent chemotactic inflammatory eicosanoid \[[@B55]\], binds to PPAR*α* and induces transcription of genes of the *ω*- and *β*-oxidation pathways that can catabolize LTB4 itself \[[@B20]\]. PPAR *α* null mice showed a prolonged inflammatory response when challenged with LTB4 or its precursor, arachidonic acid, possibly due to the absence of stimulation of the catabolic pathways, hence, the increased duration of the inflammation \[[@B20]\]. Furthermore, dietary *n*-3 fatty acids and clofibrate, which also bind to PPAR*α*, have been reported to accelerate catabolism of LTB4 in granulocytes and macrophages \[[@B56], [@B57]\]. It is postulated that activation of PPAR*α* by nonsteroidal anti-inflammatory agents contributes to the anti-inflammatory, antipyretic, and analgesic properties of these drugs through stimulation of oxidative pathways involved in the catabolism of eicosanoids \[[@B3]\]. Inhibition of the synthesis of proinflammatory molecules such as IL-6 and prostaglandins also appears to participate in PPAR*α*-mediated control of inflammation, via a decreased activity of NF-*κ*B \[[@B58]\]. Conversely, dietary treatment with PPAR*α* agonists increased lipopolysaccharide-induced plasma TNF*α* levels, an effect that was significantly diminished in PPAR*α*-deficient mice \[[@B59]\]. These latter results suggest a *pro*inflammatory role of PPAR*α*.

The postulate that PPAR*α* receptor activation enhances the degradation of lipid-derived proinflammatory mediators, such as LTB4 \[[@B20]\], is not supported by recent findings in our laboratories, using the carrageenan-induced rat paw edema model of inflammation \[[@B60]\]. First, we observed that the PPAR*α* agonist perfluorooctanoic acid (PFOA) produced robust anti-edema effects when administered minutes before carrageenan \[[@B60]\], yet de novo synthesis of enzymes requires a much longer time period, and is therefore expected to take hours following the administration of PPAR agonists. Second, when a sufficient time for de novo enzyme synthesis was allowed by administering PFOA 12 or 24 hours before carrageenan, we did not observe an enhanced anti-edema effect compared to PFOA administered only 30 minutes before carrageenan \[[@B60]\]. Consequently, we speculate that PFOA inhibits the levels of proinflammatory mediators released during the *induction* of inflammation (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [4](#F4){ref-type="fig"}).

### PPAR*γ*

Recent studies demonstrate that in addition to PPAR *α*, PPAR *γ* may also play an important role in inflammation. However, the contribution of PPAR*γ* to the inflammatory response is also unclear \[[@B53]\]. While several studies showed that PPAR*γ* activation blocked the production of *pro*inflammatory mediators \[[@B61], [@B62], [@B63], [@B64]\], other studies proposed that PPAR*γ* has no anti-inflammatory activity, or might indeed exert a *pro*-inflammatory response \[[@B53], [@B65], [@B66]\].

#### Reduction of nitric oxide (NO) production by PPAR *γ* agonists

NO acts not only as a signal molecule mediating various physiological functions, but it also plays an important role in inflammatory processes \[[@B67], [@B68]\]. Injection of LPS and IFN-*γ* into rat cerebellum induced the expression of iNOS, which produces NO, in cerebellar granule cells and caused subsequent cell death \[[@B69]\]. In this model, PPAR*γ* agonists reduced iNOS expression and cell death, whereas a selective COX-2 inhibitor had no effect \[[@B69]\]. Furthermore, mesangial cell production of NO was inhibited by PPAR*γ* agonists \[[@B70]\]. These findings suggest that PPAR*γ* regulates the activity of iNOS and activation of this PPAR subtype controls inflammation by diminishing NO production.

#### Regulation of cytokine production by PPAR*γ*

Cytokines produced by activated macrophages/foam cells, including the macrophage-colony stimulating factor, IL-1, and TNF*α*, form the basis of the inflammatory component of the atherosclerotic lesions and promote proliferation of smooth muscle cells \[[@B3]\]. Necrosis of macrophages and lipid-loaded foam cells releases their intracellular contents, resulting in an accumulation of extracellular components that form the fibrous cap of the atheromatous lesion \[[@B57]\]. Eventually, the rupture of this plaque leads to the acute arterial obstruction \[[@B3]\]. Many aspects of these pathological processes might be modulated by PPAR *γ* which is upregulated by oxidized LDL \[[@B27], [@B65]\]. Furthermore, expression of PPAR *γ* has indeed been demonstrated in mouse and human atherosclerotic lesions \[[@B27], [@B28]\]. In contrast to this apparently proatherosclerotic action of PPAR *γ* ligands, these agonists have been reported to prevent atherosclerotic plaque progression \[[@B28]\]. Further studies are needed to determine the exact role of PPAR *γ* in the development of atherosclerosis.

Our studies revealed a positive relationship between anti-edema activity of PPAR*γ* agonists in vivo \[[@B60]\] and their ability to activate PPAR*γ* in vitro \[[@B4]\]. Thus, the high affinity PPAR*γ* agonist rosiglitazone, but not the low affinity agonist troglitazone, significantly inhibited paw edema \[[@B60]\]. This suggests that, like the PPAR*α* receptor, activation of the PPAR*γ* receptor leads to anti-inflammatory effects in vivo. Also, as with the PPAR*α* agonists, rosiglitazone was effective only when given prior to, but not after, carrageenan. Therefore, PPAR*γ* also appears to regulate the *induction* phase of inflammation (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [4](#F4){ref-type="fig"}).

#### Role of PPAR*γ* in neurodegenerative and autoimmune diseases

Release of inflammatory mediators has been postulated to play a major role in the etiology of a variety of aging-related neuronal degenerative diseases, such as Alzheimer\'s disease (AD) \[[@B71]\]. The role of microglial-mediated inflammatory mechanisms in the etiology of AD has achieved prominence owing to recent compelling epidemiological and investigative findings \[[@B71]\]. Epidemiological studies have shown a reduced risk of AD among long-term users of nonsteroidal anti-inflammatory drugs (NSAIDs). The formation of amyloid plaques in AD is accompanied by the recruitment of microglia to these deposits \[[@B71]\]. The interaction of these cells with amyloid fibrils leads to their phenotypic conversion into a reactive phenotype \[[@B71]\]. The activation of microglia results in the elaboration of a diverse array of pro-inflammatory secretory products including cytokines, chemokines, reactive oxygen species, and nitrogen species, as well as of other acute phase proteins \[[@B71]\].

Previously, the anti-inflammatory actions of NSAIDs and their therapeutic benefit in treating AD were attributed to the ability of these drugs to inhibit the cyclooxygenases and PGE2 production \[[@B72]\]. Based on the findings showing that PPAR*γ* ligands prevented the increase in A*β*-stimulated COX-2 expression in microglia and monocytes \[[@B71]\], it was determined that the neuroprotective effect of NSAIDs and PPAR*γ* ligands was not attributable to a reduction in cyclooxygenase activity \[[@B71]\]. This conclusion is supported by the fact that the COX-2-specific inhibitor NS-398 failed to promote neuron survival \[[@B71]\]. Furthermore, extended use of aspirin, a potent COX inhibitor, is not associated with a reduction in the risk of AD \[[@B72]\]. Consequently, it was concluded that microglial COX-2 activity and prostaglandin production are not necessary components in the neuronal death process \[[@B71]\], and that the beneficial effects of NSAIDs in AD are attributable principally to the actions of these drugs as PPAR agonists, rather than via their ability to inhibit cyclooxygenase activity \[[@B71]\].

Several studies have also investigated the role of PPAR*γ* ligands in modifying animal models of autoimmune diseases. In a mouse model of inflammatory bowel disease, thiazolidinediones markedly reduced colonic inflammation \[[@B73]\]. It was consequently proposed that this effect might be a result of a direct effect on colonic epithelial cells, which express high levels of PPAR*γ* and can produce inflammatory cytokines \[[@B73]\]. PPAR*γ* ligands, 15d-PGJ2 and troglitazone, ameliorated adjuvant-induced arthritis with suppression of pannus formation and monouclear cell infiltration in rats \[[@B74]\]. Niino et al \[[@B75]\] examined the effect of a thiazolidinedione on experimental allergic encephalomyelitis and found that these PPAR*γ* agonists attenuated inflammation and decreased clinical symptoms in this mouse model of multiple sclerosis.

### PPAR*δ*

No published reports are available on the impact of PPAR*δ* agonists on inflammation. This may, in part, be due to the fact that PPAR*δ*-specific ligands are not readily, commercially available. Preliminary data from our laboratory show that L783483 diminished carrageenan-induced paw edema in rats ([Figure 4](#F4){ref-type="fig"}). Although this compound has PPAR*γ* activity in addition to being a PPAR*δ* agonist \[[@B13]\], the fact that it showed 2-fold efficacy in reducing paw edema compared to the potent PPAR*γ* agonist rosiglitazone ([Figure 4](#F4){ref-type="fig"}) suggests that PPAR*δ* may also play a role in controlling inflammatory responses. It remains to be investigated, however, whether L783483 modulates paw edema if administered after the induction of inflammation by carrageenan, as was the case with agonists of both PPAR*α* and PPAR*γ* ([Figure 2](#F2){ref-type="fig"}).

The development of edema in the rat paw following the intraplantar injection of carrageenan has been described as a biphasic event (see [Table 2](#T2){ref-type="table"}) \[[@B14], [@B15], [@B16], [@B76]\]. In response to carrageenan-induced paw edema, it has been documented that while cNOS appears to be involved in the early phase of inflammation, iNOS participates in the sustained phase \[[@B15], [@B16]\]. Early in the inflammatory response to carrageenan, while infilterating neutrophils are not the source of iNOS-derived NO \[[@B15], [@B16]\], these cells appear to contributeO~2~^−^ to the early phase of inflammation \[[@B15], [@B16]\]. Therefore, our findings \[[@B60]\] suggest that anti-inflammatory effects of PPAR agonist are likely due to the ability of these chemicals to interfere with cNOS, but not with iNOS. Given the above studies, the relevance of PPARs and the utility of treatment with PPAR agonists in diseases with inflammatory or autoimmune pathogenesis will likely continue to remain a research focus.

PPAR-independent anti-inflammatory effects of PPAR agonists
-----------------------------------------------------------

Several recent studies report that agonists of both PPAR*α* and PPAR*γ* produce effects that are not mediated by PPARs. However, the nature of these PPAR-independent mechanisms is not understood at this time.

### PPAR*α* agonists

In a most recent report \[[@B77]\], treatment of splenocytes with the PPAR*α* agonist Wy-14,643 as well as by other fibrates led to marked increases in Interleukin-4 (IL-4) release. Surprisingly, however, Wy-14,643 also induced IL-4 expression in splenocytes from PPAR*α* knockout mice \[[@B77]\]. Furthermore, GW 7,647, a potent and specific PPAR*α* ligand, did not augment IL-4 under conditions used with Wy-14,643 \[[@B77]\]. These findings suggest that modulating inflammatory responses exerted by Wy-14,643 and by other fibrates in lymphocytes may not be mediated exclusively through PPAR*α*-dependent mechanisms \[[@B77]\].

### PPAR*γ* agonists

Numerous studies present evidence for receptor-independent anti-inflammatory effects caused by PPAR*γ* agonists \[[@B69], [@B70], [@B73], [@B75]\]. A study showed that the PPAR*γ* agonist troglitazone enhanced IL-1-induced nitric oxide synthase (NOS) mRNA levels in vascular smooth muscle cells despite the absence of detectable PPAR*γ* levels in these cells \[[@B64]\]. However, these effects were in contrast to those obtained in response to 15-deoxy-$\Delta^{12,14}$ prostaglandin J~2~, the natural ligand for PPAR*γ* \[[@B78]\]. Another study \[[@B79]\] reports that both 15-deoxy-$\Delta^{12,14}$ prostaglandin J~2~ and the thiazolidinedione drugs have anti-inflammatory effects that are independent of PPAR*γ*. Furthermore, in activated microglia, while 15-deoxy-$\Delta^{12,14}$ prostaglandin J~2~ suppressed iNOS promotor activity and decreased its mRNA and protein levels, troglitazone, a specific PPAR*γ* ligand, failed to produce similar effects \[[@B80]\]. These findings further support the conclusion that anti-inflammatory action exerted by 15-deoxy-$\Delta^{12,14}$ prostaglandin J~2~ may involve sites other than PPAR*γ* \[[@B80]\]. Indeed, it has been shown that the two structurally similar thiazolidinediones troglitazone and rosiglitazone cause different conformational changes in the PPAR*γ*, upon binding to this receptor \[[@B81]\]. Further, troglitazone may behave as a partial agonist under certain physiological circumstances, and as a full agonist under others \[[@B81]\].

The exact mechanisms involved in these non-PPAR-mediated effects of PPAR agonists are not well understood. However, it is possible that these agonists act via receptors other than PPARs to affect changes in the synthesis and/or release of pro-inflammatory mediators ([Figure 3](#F3){ref-type="fig"}). Alternatively, PPAR agonists may act via a nonreceptor-mediated mechanism such as antioxidants or free-radical scavengers ([Figure 3](#F3){ref-type="fig"}). The latter potential is supported by experimental findings showing that administering exogenous antioxidants, for example, vitamin E-like compounds, or elements of the endogenous cellular antioxidant defense mechanisms, for example, superoxide dismutase, exhibited protective effects against inflammatory insults \[[@B82]\].

SUMMARY AND CONCLUSIONS
=======================

Demonstrating that PPAR agonists diminished inflammatory responses in several experimental models of inflammation has led to a surge in interest in these agonists as potential therapeutic agents to treat inflammatory diseases. Although various postulates have been advanced in an attempt to explain the mode of action of these compounds as anti-inflammatory agents, the exact mechanism by which they act remains elusive. Our recent results strongly suggest that agonists of PPAR*α* and PPAR*γ* interfere with the early phase of inflammation, without influencing its late phase. An unpublished finding from our laboratories shows that activation of PPAR*δ* also elicits an anti-inflammatory response. It is not yet clear, however, whether these three PPAR receptor subtypes share a common mechanism or act independently to control inflammatory processes.

FUTURE DIRECTIONS
=================

The PPAR-independent anti-inflammatory effects of PPAR agonists warrant investigation to localize potential non-PPAR site(s) of action of these compounds. A vast amount of circumstantial evidence implicates oxygen-derived free radicals (especially superoxide and hydroxyl radical) and high-energy oxidants (such as peroxynitrite) as mediators of inflammation \[[@B16]\]. Production of reactive oxygen species (ROS) such as O~2~^−^, H~2~O~2~, and HO^.^ occurs at the site of inflammation and contributes to tissue damage \[[@B16]\]. Interventions which reduce the generation, and/or the effects of ROS exert beneficial effects in a variety of models of inflammation \[[@B83]\]. Since superoxide dismutase (SOD), but not catalase, the iron-chelator desferrioxamine or serine protease inhibitor, has been shown to attenuate neutrophil-mediated cell injury \[[@B84]\], it is strongly suggested that O~2~^−^ plays a major role in neutrophil-induced inflammation. Interestingly, SOD mimetics are superior to SOD in attenuating neutrophil-mediated cell injury \[[@B84], [@B85]\], possibly because of their superior intracellular accessibility and also due to the fact that these compounds, in contrast to SOD, do not react with H~2~O~2~, a reaction which is known to result in the formation of HO^.^ via Fenton chemistry \[[@B85]\].

In addition to ROS, it has also been reported that NO^.^ plays a role in the pathophysiology associated with various models of inflammation \[[@B15], [@B86], [@B87]\]. In addition to NO^.^, ONOO^−^ is also generated during inflammation \[[@B15]\]. In arthritis, nitrotyrosine levels increase in plasma and synovial fluid \[[@B88]\]. In ileitis \[[@B89]\] and in endotoxin-induced intestinal inflammation, there is immunocytochemical documentation of augmented ONOO^−^ production \[[@B90]\]. The pathophysiological role of NO^.^ and ONOO^−^ in the gastrointestinal damage elicited by endotoxin or chronic inflammation has been the subject of a variety of detailed investigations \[[@B91]\]. The ability of ONOO^−^ to cause severe colonic inflammation has been documented \[[@B91]\], and the production of ONOO^−^ in colitis may be even more pronounced because of the parallel down-regulation of SOD \[[@B92]\], which makes the O~2~^−^ available for coupling with NO^.^ \[[@B92]\]. It is reported that PPAR agonists decrease NOS activity and the production of NO in experimental inflammation models \[[@B29], [@B62]\]. However, the question of whether agonists of PPARs act as SOD mimetics, or via other mechanisms, to neutralize ROS deserves an answer and it is currently being planned to investigate this exciting potential.
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